Symbols / AXGN Stock $43.28 +0.19% Axogen, Inc.

Healthcare • Medical Devices • United States • NCM
AXGN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Michael D. Dale
Exch · Country NCM · United States
Market Cap 2.30B
Enterprise Value 2.22B
Income -31.45M
Sales 238.10M
FCF (ttm) 18.29M
Book/sh 2.73
Cash/sh 1.91
Employees 622
Insider 10d —
IPO Dec 17, 1986
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 56.82
PEG 99.04
P/S 9.67
P/B 15.85
P/C —
EV/EBITDA -1,040.08
EV/Sales 9.33
Quick Ratio 4.99
Current Ratio 7.10
Debt/Eq 8.43
LT Debt/Eq —
EPS (ttm) -0.64
EPS next Y 0.76
EPS Growth —
Revenue Growth 26.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-28
Earnings (prior) 2026-04-28
ROA -2.32%
ROE -17.96%
ROIC —
Gross Margin 75.01%
Oper. Margin -4.61%
Profit Margin -13.21%
Shs Outstand 53.18M
Shs Float 52.03M
Insider Own 2.05%
Instit Own 87.21%
Short Float 7.37%
Short Ratio 3.94
Short Interest 3.73M
52W High 45.83
vs 52W High -5.56%
52W Low 9.22
vs 52W Low 369.41%
Beta 0.98
Impl. Vol. 69.17%
Rel Volume 0.72
Avg Volume 1.05M
Volume 759.23K
Target (mean) $50.78
Tgt Median $50.00
Tgt Low $48.00
Tgt High $55.00
# Analysts 9
Recom Strong_buy
Prev Close $43.20
Price $43.28
Change 0.19%
About

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$50.78
Mean price target
2. Current target
$43.28
Latest analyst target
3. DCF / Fair value
$6.19
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$43.28
Low
$48.00
High
$55.00
Mean
$50.78

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-29 main Canaccord Genuity Buy → Buy $50
2026-04-29 main Citizens Market Outperform → Market Outperform $50
2026-04-29 main Wells Fargo Overweight → Overweight $48
2026-04-29 main HC Wainwright & Co. Buy → Buy $50
2026-04-23 main Lake Street Buy → Buy $50
2026-03-30 main Canaccord Genuity Buy → Buy $40
2026-02-24 main Citizens Market Outperform → Market Outperform $42
2026-02-19 init Wells Fargo — → Overweight $40
2025-12-05 main Canaccord Genuity Buy → Buy $37
2025-12-05 main HC Wainwright & Co. Buy → Buy $39
2025-12-04 main Jefferies Buy → Buy $36
2025-12-04 main Lake Street Buy → Buy $40
2025-12-01 init Mizuho — → Outperform $40
2025-10-30 main HC Wainwright & Co. Buy → Buy $26
2025-10-30 main Raymond James Outperform → Outperform $27
2025-10-30 main Canaccord Genuity Buy → Buy $27
2025-10-30 main Citizens Market Outperform → Market Outperform $34
2025-09-30 init HC Wainwright & Co. — → Buy $25
2025-05-13 main Canaccord Genuity Buy → Buy $24
2025-03-17 init Lake Street — → Buy $30
News
RSS: Latest AXGN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-16 DEVINNEY ERICK WAYNE Officer — 5,221 $32.84 $171,458
2026-03-16 DEVINNEY ERICK WAYNE Officer — 17,938 — —
2026-03-16 HARTLEY LINDSEY MARIE Chief Financial Officer — 9,000 — —
2026-02-27 BEGAN MARC A. General Counsel — 11,250 — —
2026-02-26 DEVINNEY ERICK WAYNE Officer — 33,780 $0.00 $0
2026-02-26 BEGAN MARC A. General Counsel — 33,780 $0.00 $0
2026-02-26 KEMP JENS SCHROEDER Officer — 50,670 $0.00 $0
2026-02-26 HARTLEY LINDSEY MARIE Chief Financial Officer — 17,453 $0.00 $0
2026-02-20 HARTLEY LINDSEY MARIE Chief Financial Officer — 17,500 $0.00 $0
2025-12-16 MCBRIDE-WENDELL AMY A. Director — 43,684 $29.31 $1,280,465
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
225.21
+20.21%
187.34
+17.81%
159.01
+14.74%
138.58
Operating Revenue
225.21
+20.21%
187.34
+17.81%
159.01
+14.74%
138.58
Cost Of Revenue
57.85
+27.54%
45.36
+22.13%
37.14
+24.75%
29.77
Reconciled Cost Of Revenue
57.85
+27.54%
45.36
+22.13%
37.14
+24.75%
29.77
Gross Profit
167.35
+17.87%
141.98
+16.50%
121.87
+12.00%
108.81
Operating Expense
175.20
+20.61%
145.26
+1.35%
143.33
+3.48%
138.52
Research And Development
32.88
+18.43%
27.77
+1.57%
27.34
+6.68%
25.63
Selling General And Administration
142.32
+21.12%
117.50
+1.30%
115.99
+2.75%
112.89
Selling And Marketing Expense
97.74
+24.57%
78.46
+1.14%
77.58
+7.78%
71.98
General And Administrative Expense
44.58
+14.19%
39.04
+1.62%
38.41
-6.10%
40.91
Other Gand A
44.58
+14.19%
39.04
+1.62%
38.41
-6.10%
40.91
Total Expenses
233.06
+22.26%
190.62
+5.62%
180.47
+7.24%
168.29
Operating Income
-7.85
-138.79%
-3.29
+84.68%
-21.46
+27.75%
-29.71
Total Operating Income As Reported
-7.85
-138.79%
-3.29
+84.68%
-21.46
+27.75%
-29.71
EBITDA
0.51
-91.66%
6.08
+145.61%
-13.33
+43.22%
-23.47
Normalized EBITDA
0.83
-81.02%
4.35
+126.62%
-16.35
+34.83%
-25.08
Reconciled Depreciation
8.51
+8.56%
7.84
+41.13%
5.55
+14.42%
4.85
EBIT
-8.00
-355.12%
-1.76
+90.69%
-18.88
+33.34%
-28.32
Total Unusual Items
-0.32
-118.46%
1.73
-42.74%
3.02
+87.10%
1.61
Total Unusual Items Excluding Goodwill
-0.32
-118.46%
1.73
-42.74%
3.02
+87.10%
1.61
Net Income
-15.70
-57.60%
-9.96
+54.12%
-21.72
+24.98%
-28.95
Pretax Income
-15.70
-57.60%
-9.96
+54.12%
-21.72
+24.98%
-28.95
Net Non Operating Interest Income Expense
-7.70
+6.14%
-8.21
-189.45%
-2.83
-354.33%
-0.62
Interest Expense Non Operating
7.70
-6.14%
8.21
+189.45%
2.83
+354.33%
0.62
Net Interest Income
-7.70
+6.14%
-8.21
-189.45%
-2.83
-354.33%
-0.62
Interest Expense
7.70
-6.14%
8.21
+189.45%
2.83
+354.33%
0.62
Other Income Expense
-0.15
-109.94%
1.53
-40.76%
2.58
+86.62%
1.38
Other Non Operating Income Expenses
0.17
+183.92%
-0.20
+54.46%
-0.44
-90.00%
-0.23
Gain On Sale Of Security
-0.32
-118.46%
1.73
-42.74%
3.02
+87.10%
1.61
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-15.70
-57.60%
-9.96
+54.12%
-21.72
+24.98%
-28.95
Net Income From Continuing Operation Net Minority Interest
-15.70
-57.60%
-9.96
+54.12%
-21.72
+24.98%
-28.95
Net Income From Continuing And Discontinued Operation
-15.70
-57.60%
-9.96
+54.12%
-21.72
+24.98%
-28.95
Net Income Continuous Operations
-15.70
-57.60%
-9.96
+54.12%
-21.72
+24.98%
-28.95
Normalized Income
-15.38
-31.58%
-11.69
+52.73%
-24.73
+19.07%
-30.56
Net Income Common Stockholders
-15.70
-57.60%
-9.96
+54.12%
-21.72
+24.98%
-28.95
Diluted EPS
-0.34
-47.83%
-0.23
+54.90%
-0.51
+26.09%
-0.69
Basic EPS
-0.34
-47.83%
-0.23
+54.90%
-0.51
+26.09%
-0.69
Basic Average Shares
46.05
+4.05%
44.26
+3.22%
42.88
+1.89%
42.08
Diluted Average Shares
46.05
+4.05%
44.26
+3.22%
42.88
+1.89%
42.08
Diluted NI Availto Com Stockholders
-15.70
-57.60%
-9.96
+54.12%
-21.72
+24.98%
-28.95
Line Item Trend 2023-12-31
Total Assets
196.83
Current Assets
88.00
Cash Cash Equivalents And Short Term Investments
31.02
Cash And Cash Equivalents
31.02
Other Short Term Investments
0.00
Receivables
25.15
Accounts Receivable
25.15
Gross Accounts Receivable
25.48
Allowance For Doubtful Accounts Receivable
-0.34
Inventory
23.02
Raw Materials
7.36
Work In Process
2.12
Finished Goods
13.54
Prepaid Assets
—
Restricted Cash
6.00
Other Current Assets
2.81
Total Non Current Assets
108.82
Net PPE
104.29
Gross PPE
117.99
Accumulated Depreciation
-13.70
Properties
0.00
Land And Improvements
0.73
Buildings And Improvements
60.68
Machinery Furniture Equipment
8.74
Construction In Progress
3.67
Other Properties
28.82
Leases
15.35
Goodwill And Other Intangible Assets
4.53
Other Intangible Assets
4.53
Total Liabilities Net Minority Interest
101.16
Current Liabilities
30.43
Payables And Accrued Expenses
14.95
Payables
11.77
Accounts Payable
11.77
Current Accrued Expenses
3.18
Pensionand Other Post Retirement Benefit Plans Current
13.93
Current Debt And Capital Lease Obligation
1.55
Current Capital Lease Obligation
1.55
Total Non Current Liabilities Net Minority Interest
70.73
Long Term Debt And Capital Lease Obligation
67.75
Long Term Debt
46.60
Long Term Capital Lease Obligation
21.14
Other Non Current Liabilities
—
Stockholders Equity
95.67
Common Stock Equity
95.67
Capital Stock
0.43
Common Stock
0.43
Share Issued
43.12
Ordinary Shares Number
43.12
Treasury Shares Number
0.00
Additional Paid In Capital
376.53
Retained Earnings
-281.30
Total Equity Gross Minority Interest
95.67
Total Capitalization
142.27
Working Capital
57.57
Invested Capital
142.27
Total Debt
69.29
Net Debt
15.58
Capital Lease Obligations
22.69
Net Tangible Assets
91.13
Tangible Book Value
91.13
Derivative Product Liabilities
2.99
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
0.81
-82.09%
4.54
+179.34%
-5.72
+64.42%
-16.07
Cash Flow From Continuing Operating Activities
0.81
-82.09%
4.54
+179.34%
-5.72
+64.42%
-16.07
Net Income From Continuing Operations
-15.70
-57.60%
-9.96
+54.12%
-21.72
+24.98%
-28.95
Depreciation Amortization Depletion
8.51
+8.56%
7.84
+41.13%
5.55
+14.42%
4.85
Depreciation
8.19
+8.23%
7.57
+43.37%
5.28
+15.08%
4.59
Amortization Cash Flow
0.32
+17.98%
0.27
-2.20%
0.27
+3.02%
0.27
Depreciation And Amortization
8.51
+8.56%
7.84
+41.13%
5.55
+14.42%
4.85
Amortization Of Intangibles
0.32
+17.98%
0.27
-2.20%
0.27
+3.02%
0.27
Other Non Cash Items
0.89
-0.22%
0.89
+0.22%
0.89
+0.00%
0.89
Stock Based Compensation
30.11
+89.31%
15.91
+10.32%
14.42
-7.52%
15.59
Provisionand Write Offof Assets
0.40
-38.46%
0.65
+339.85%
-0.27
-144.28%
0.61
Asset Impairment Charge
0.06
0.00
0.00
-100.00%
1.77
Operating Gains Losses
1.16
+256.06%
-0.74
+65.34%
-2.14
-68.32%
-1.27
Gain Loss On Investment Securities
1.16
+256.06%
-0.74
+66.23%
-2.20
-72.72%
-1.27
Gain Loss On Sale Of PPE
0.00
0.00
-100.00%
0.06
0.00
Change In Working Capital
-24.61
-145.07%
-10.04
-310.34%
-2.45
+68.59%
-7.79
Change In Receivables
-2.46
-728.57%
0.39
+114.57%
-2.69
+41.99%
-4.64
Changes In Account Receivables
-2.46
-728.57%
0.39
+114.57%
-2.69
+41.99%
-4.64
Change In Inventory
-9.19
+9.57%
-10.16
-146.97%
-4.12
-118.07%
-1.89
Change In Prepaid Assets
-3.90
-598.09%
0.78
+190.43%
-0.87
-932.14%
-0.08
Change In Payables And Accrued Expense
-7.16
-5826.40%
0.12
-98.08%
6.51
+886.21%
0.66
Change In Payable
—
—
—
—
Change In Account Payable
—
—
—
—
Change In Other Working Capital
—
0.42
+3128.57%
-0.01
—
Change In Other Current Liabilities
-1.89
-60.31%
-1.18
+8.11%
-1.28
+30.31%
-1.84
Investing Cash Flow
-5.32
+48.36%
-10.30
-153.48%
19.25
+701.66%
-3.20
Cash Flow From Continuing Investing Activities
-5.32
+48.36%
-10.30
-153.48%
19.25
+701.66%
-3.20
Net PPE Purchase And Sale
-3.75
-20.77%
-3.10
+77.65%
-13.87
+30.91%
-20.08
Purchase Of PPE
-3.75
-20.77%
-3.10
+77.65%
-13.87
+30.91%
-20.08
Capital Expenditure
-5.59
-23.65%
-4.52
+69.67%
-14.92
+29.81%
-21.25
Net Investment Purchase And Sale
0.28
+104.80%
-5.77
-116.89%
34.17
+89.28%
18.05
Purchase Of Investment
-13.72
-137.71%
-5.77
+43.42%
-10.20
+74.00%
-39.25
Sale Of Investment
14.00
0.00
-100.00%
44.37
-22.56%
57.30
Net Intangibles Purchase And Sale
-1.85
-29.94%
-1.42
-36.04%
-1.05
+10.98%
-1.18
Purchase Of Intangibles
-1.85
-29.94%
-1.42
-36.04%
-1.05
+10.98%
-1.18
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
10.50
+358.47%
2.29
+17.20%
1.95
+8.92%
1.79
Cash Flow From Continuing Financing Activities
10.50
+358.47%
2.29
+17.20%
1.95
+8.92%
1.79
Net Issuance Payments Of Debt
-0.03
-220.00%
-0.01
+0.00%
-0.01
+16.67%
-0.01
Issuance Of Debt
—
—
0.00
0.00
Repayment Of Debt
-0.03
-220.00%
-0.01
+0.00%
-0.01
+16.67%
-0.01
Long Term Debt Issuance
—
—
0.00
0.00
Long Term Debt Payments
-0.03
-220.00%
-0.01
+0.00%
-0.01
+16.67%
-0.01
Net Long Term Debt Issuance
-0.03
-220.00%
-0.01
+0.00%
-0.01
+16.67%
-0.01
Net Common Stock Issuance
—
—
—
0.00
Proceeds From Stock Option Exercised
10.53
+357.87%
2.30
+17.11%
1.96
+8.75%
1.81
Changes In Cash
5.99
+272.64%
-3.47
-122.41%
15.49
+188.66%
-17.47
Beginning Cash Position
33.55
-9.38%
37.03
+71.93%
21.54
-44.79%
39.01
End Cash Position
39.55
+17.86%
33.55
-9.38%
37.03
+71.93%
21.54
Free Cash Flow
-4.78
-43572.73%
0.01
+100.05%
-20.63
+44.71%
-37.32
Interest Paid Supplemental Data
6.81
-6.71%
7.30
+275.57%
1.94
0.00
Common Stock Issuance
—
—
—
0.00
Interest Paid CFO
-0.01
-175.00%
-0.00
-33.33%
-0.00
-50.00%
-0.00
Issuance Of Capital Stock
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category